BATF3 and neoplasm: In addition, Batf3−/− mice can still achieve partial tumor control and mount tumor-specific CTL response under low-dose tumor challenge (35, 51, 54), which might be explained either by the incomplete cDC1 loss or by partial redundancy between cDC1 and other cell types for the cross-presentation of cellular Ag and the induction of antitumor adaptive immunity.